USAN Watch - October 2010

12 Oct 2010

The October 2010 USANs have just been published, these are:

USAN	Research code	Drug Type	Drug Class	Target
bedaquiline	TMC-207, R-207910	small molecule	therapeutic	ATP synthase
bedaquiline fumarate	TMC-207, R-403323	small molecule	therapeutic	ATP synthase
edivoxetine hydrochloride	LY-2216684	small molecule	therapeutic	NET
eteplirsen	AVI-4658	oligonucleotide	therapeutic
latrepirdine dihydrochloride	dimebolin, Dimebon	small molecule	therapeutic	complex (inc. NMDAr, AMPAr, L-type Ca channel, alpha receptors, 5HT2C, 5HT5A, 5HT6, H1 H2)
lenvatinib	ER-203492, E-7080	small molecule	therapeutic	VEGFR2
naronapride	ATI-7505	small molecule	therapeutic	5HT4R
naronapride dihydrohloride	ATI-7505	small molecule	therapeutic	5HT4R
onartuzumab	PRO143966, MetMAb	mAb	therapeutic	Scatter Factor receptor
ornithine phenylacetate	OCR-002, L-OP, OP	small molecule	therapeutic	n/a
peginesatide acetate	AF-37702	peptide	therapeutic	EPOr
pomaglumated methionil	LY-2140023	small molecule	therapeutic	mGluR2/3
secukinumab	AIN-457	mAb	therapeutic	IL-17A
semaglutide	NNC-0113-0217	peptide	therapeutic	GLP1R

There are 10 distinct drug structures here (some are parent and salt pairs), six are synthetic small molecules, largely from established target classes, and four are biological drugs. Latrepirdine a.k.a. Dimebon is a molecule showing broad pharmacology, and a rollercoaster ride through licensing and development.